| Objective This study was aimed to explore the induction of acute myeloid leukemia cells immunogenicity apoptosis by bortezimibin combination with idarubicin, and to provide experimental basis for the treatment of acute leukemia.Methods Isolate mononuclear cells from the peripheral blood or bone marrow of new diagnosed AML patients by lymphocyte separation medium and density gradient centrifugation. Then detect CD34+CD38+ cells and CD34+CD38-cells by flow cytometry. Induce mononuclear cells by idarubicin and (or) bortezimibin. Detect the apoptosis rate and CRT expression rate on cell surface of CD34+CD38+ cells and CD34+CD38- cells. Analysis the apoptosis rate and immunogenicity (CRT expression rate) between CD34+CD38+ cells and CD34+CD38-cells; and the two drugs affection on apoptosis rate and immunogenicity (CRT expression rate)of cells.Results 1. The apoptosis rate and CRT expression rate of CD34+CD38+ cells were higher than CD34+CD38- cells in IDA group; 2. The apoptosis rate and CRT expression rate of CD34+CD38- cells were higher than CD34+CD38+ cells in Bortezimibin group; 3. The apoptosis rate and CRT expression rate of CD34+CD38+ cells were higher than CD34+CD38-cells in IDA+ Bortezimibin group; 4. There has no significant difference between IDA group and Bortezimibin group on apoptosis rate and CRT expression rate of CD34+CD38+ cells.5. There has no significant difference between IDA group and Bortezimibin group on apoptosis rate and CRT expression rate of CD34+CD38-cells.6 The CD34+CD38+ cells apoptosis rate and CRT expression rate in IDA+ Bortezimibin group were significantly higher than IDA group and Bortezimibin group.7. The CD34+ CD38- cells apoptosis rate and CRT expression rate in IDA+ Bortezimibin group were significantly higher than IDA group and Bortezimibin group.Conclusions Idarubicin, bortezimibin and their combination can induce immunogenicity apoptosis of CD34+CD38+ cells and CD34+CD38-cells. |
PDF Full Text Request